Open Label Phase IIa Study Evaluating the Safety and Efficacy of NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Bezisterim (Primary)
- Indications Traumatic brain injuries
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 17 Jul 2024 Planned End Date changed from 21 Jul 2024 to 21 Jul 2025.
- 17 Jul 2024 Planned primary completion date changed from 21 Jun 2024 to 21 Dec 2024.
- 17 Jul 2024 Status changed from not yet recruiting to recruiting.